Sheel Biotech (NSE:SHEEL) EBIT: ₹159 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHEEL Sheel Biotech Ltd NSE:SHEEL
18 GF Score
Price ₹68.00
! 2 Warning Signs
View Full Analysis

What is Sheel Biotech EBIT?

Sheel Biotech NSE:SHEEL 18 EBIT is ₹159 Mil as of Mar. 2026. GuruFocus rates NSE:SHEEL with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Sheel Biotech's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹159 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹159 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sheel Biotech's annualized ROC % for the quarter that ended in Mar. 2026 was 10.29%. Sheel Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sheel Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.97%.

Sheel Biotech  (NSE:SHEEL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sheel Biotech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=152.177 * ( 1 - 16.12% )/( (1076.688 + 1405.413)/ 2 )
=127.6460676/1241.0505
=10.29 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1132.826 - 51.497 - ( 4.641 - max(0, 240.162 - 1010.918+4.641))
=1076.688

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1457.843 - 30.601 - ( 21.829 - max(0, 169.728 - 1278.274+21.829))
=1405.413

Note: The Operating Income data used here is one times the annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sheel Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=159.304/( ( (74.743 + max(891.244, 0)) + (129.203 + max(1134.46, 0)) )/ 2 )
=159.304/( ( 965.987 + 1263.663 )/ 2 )
=159.304/1114.825
=14.29 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(550.791 + 393.853 + 61.375) - (51.497 + 0 + 63.278)
=891.244

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(618.05 + 295.651 + 313.134) - (30.601 + 0 + 61.774)
=1134.46

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sheel Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=159.304/1451.935
=10.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sheel Biotech EBIT Related Terms

Sheel Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Sheel Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sheel Biotech EBIT Chart

Sheel Biotech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
55.03 75.09 135.58 145.90 159.30

Sheel Biotech Semi-Annual Data
Mar22 Mar23 Mar24 Mar25 Mar26
EBIT 55.03 75.09 135.58 145.90 159.30

NSE:SHEEL vs ADM, BG, TSN: EBIT Comparison

For the Farm Products subindustry, Sheel Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sheel Biotech EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sheel Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sheel Biotech's EV-to-EBIT falls into.


NSE:SHEEL
18GF Score
Sheel Biotech Ltd NSE:SHEEL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sheel Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹159 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹159 Mil mean?
Sheel Biotech (NSE:SHEEL) has a EBIT of ₹159 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sheel Biotech.
Is Sheel Biotech's EBIT too high?
Sheel Biotech's current EBIT is ₹159 Mil. Overall, Sheel Biotech has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sheel Biotech's EBIT compare to ADM and BG?
Sheel Biotech's EBIT of ₹159 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sheel Biotech. Sheel Biotech's current EBIT is ₹159 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sheel Biotech stock overvalued right now?
Sheel Biotech (NSE:SHEEL) has a current EBIT of ₹159 Mil. The current EBIT is ₹159 Mil. Sheel Biotech's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sheel Biotech (NSE:SHEEL), the current EBIT is ₹159 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sheel Biotech Business Description

Address Guru Ravidas Marg, 8 Balaji Estates, 2nd Floor, Block-C, Kalkaji, South Delhi, New Delhi, IND, 110019
Sheel Biotech Ltd is engaged in the business of growing, developing, processing, and supplying a wide range of plants for field crops, fruits, vegetables, and ornamental plants through tissue culture and organic farming. It manufactures and maintain greenhouses, offer services to farmers and provide training through Farmer Producer Organizations (FPOs). The company also has a Research and Development lab with a capacity of production of 10 million* planting materials which is duly recognized by the Department of Biotechnology (DBT), Government of India.
18GF Score

Get the complete analysis for NSE:SHEEL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹68.00
Price